TABLE 3.

Distribution of antimicrobial susceptibilities of Staphylococcus lugdunensis clinical isolates

Antimicrobial agent and parametera% of isolates with MIC or MBC at or below the following concn (μg/ml)b:
0.030.060.1250.250.51248163264128
CFZ
    MIC20c67100
    MBC7c407393100
DAP
    MIC215093100
    MBC14293679100
LZD
    MIC13100
    MBC100d
MXF
    MIC87100
    MBC608093100
NAF
    MIC47100
    MBC207387100
Q-D
    MIC727608087100
    MBC713536773100e
RIF
    MIC100f
    MBC20404753100e
TET
    MIC20276780100
    MBC100e
SXTg
    MIC47678793100h
    MBC202740100h
VAN
    MIC2787100
    MBC720100d
  • a CFZ, cefazolin; DAP, daptomycin; LZD, linezolid; MXF, moxifloxacin; NAF, nafcillin; RIF, rifampin; Q-D, quinupristin-dalfopristin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin.

  • b Percentage of clinical S. lugdunensis isolates (n was 15 for all drugs except daptomycin, for which n was 14). S. lugdunensis isolates and the methods used for susceptibility testing were described previously (67).

  • c MIC or MBC ≤ 0.125.

  • d MBC > 128.

  • e MBC > 32.

  • f MIC ≤ 0.03.

  • g SXT susceptibility values correspond to trimethoprim concentrations.

  • h MIC or MBC > 16.